Dr Golnaz Borghei joint Ventac Partners in early 2016.
Golnaz received her PhD from University of Cambridge in Biotechnology and genetic engineering, where her work on building novel medical diagnostics and biosensors has been published by NATO book series in portable Chemical Sensors and front cover of Analyst.
Golnaz’ several years of postdoctoral research at Cambridge and Oxford universities has been focused on Neuroscience and electrophysiology on development and imaging of novel CNS drugs. She has led multiple cross-border industry/research collaborations with leading institutes such as Perkin Elmer and US National Academy of Sciences.
Backed by solid technical background, Golnaz is specialized in business development of early stage biotech and medtech companies, both pre- and post-IPO, competitive intelligence, expanding partnerships and fundraising. Golnaz has also been advisor to family offices and venture capitals in North Europe and the UK on business evaluation and technology and market assessment for heath-tech investment opportunities.
Dr Borghei is certified from Harvard Business School in executive finance, and is specialized in financial valuation of early stage biotech companies and projects through building business cases, detailed discounted cash flow (DCF) analysis, risk and scenario analysis and similar deal-term transactions.
Lived and worked in the UK, North Europe and the Middle East, Golnaz has a global perspective to entrepreneurship and is a jury member, lecturer and mentor for several life science accelerators, including Cambridge-based Innovation Forum and Scandinavia Venture Cup.